Navigation Links
Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
Date:6/6/2011

PITTSBURGH, June 6, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. demonstrated data supporting the utility of cell line-derived multi-gene predictors in the prediction of preoperative chemotherapy response in early stage breast cancer at the 2011 ASCO Annual Meeting on June 4, 2011 in Chicago, Illinois.  The study, titled, Multigene Predictors Developed on Breast Cancer Cell Lines to Predict Patient Chemotherapy Response:  A Validation Study on the NSABP B-27 Trial, combined the genomic profiles of cell lines with their in vitro chemoresponse data to identify genes whose expression was associated with drug response.  The resulting MGP was used to predict chemotherapy response in patients.

"Clinical interests currently lie in identifying patients most responsive to specific chemotherapy agents to maximize the benefit of treatment and to minimize unnecessary side effects," stated Kui Shen, Ph.D., a bioinformatics scientist and co-author of the study. "By combining ChemoFx® chemosensitivity data from cell lines with their genomic profiles, Precision has developed a procedure to derive gene signatures that may predict a patient's chemotherapy response prior to treatment. This approach is now confirmed using NSABP B-27 clinical data, showing an accuracy of as high as 75%."

Precision continues to seek and develop strategic products that fit within the cancer care continuum, including multi-gene predictors to help with choosing treatments for triple negative women.  Precision has completed 12 separate validations including both NSABP and U.S. Oncology trials.

About Precision Therapeutics

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care.  Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. 

About ChemoFx®

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. For more information, please visit www.precisiontherapeutics.com, or www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers
2. Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR
3. Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer
4. Boston Scientific Receives FDA Approval of New Clik(TM) Anchor for Precision Plus(TM) Spinal Cord Stimulator System
5. Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011
6. Source Precision Medicine, Inc., dba SourceMDx Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. of the firm of Finn, Warnke & Gayton, LLP
7. Applied Precision Exhibit at the Biophysical Society Annual Meeting Showcases New Microscopy Solutions for Life Science Industries
8. TechPrecision Corporation Receives New $450,000 Medical Purchase Order
9. Applied Precision Scientific Team to Present 3D-SIM Paper at BiOS in San Francisco
10. Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico
11. Exempla Saint Joseph Hospital Commences Treating Cancer Patients Using New TrueBeam™ System for High-Precision Image-Guided Radiotherapy and Radiosurgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):